Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Study Tests Islet Transplants for Severe Diabetes
Uncategorized

New Study Tests Islet Transplants for Severe Diabetes

By medwebMay 5, 2008
Share
Facebook Twitter Email

New Study Tests Islet Transplants for Severe Diabetes

Not all patients with type 1 diabetes are able to achieve good control of their blood sugar with multiple daily insulin injections. Some patients still suffer episodes of dangerously low levels of blood sugar and others—who can’t sense the drop in their blood sugar—may suddenly lose consciousness without warning.

Researchers at Northwestern University’s Feinberg School of Medicine and Northwestern Memorial Hospital have been performing experimental transplants of islet cells—insulin producing cells from the pancreas—for the past ten years to enable these patients to become insulin free or greatly reduce their need for it. Northwestern was the first center in Illinois to perform these transplants.

Now the Feinberg School and the hospital are launching a National Institutes of Health clinical trial for islet transplantation for adults with difficult to control type 1 diabetes and diabetic patients who have had a kidney transplant. Diabetes is the leading cause of kidney failure. Type 1 diabetes cuts lives short by about 15 years, due mainly to heart attacks and strokes.

“This novel approach is appealing because it provides a very specific therapy for the disease and eliminates many of the surgical and post- operative risks associated with pancreas transplantation,” said Dixon B. Kaufman, MD, principal investigator for the Northwestern study (part of an international multi-site study) and professor of organ transplantation as well as vice chair of surgery at the Feinberg School.

“These studies may open the door to more widespread use of islet transplantation for patients with severe type 1 diabetes,” said Kaufman, who directs the pancreas and islet cell transplant program at Northwestern Memorial.

The Kaufman laboratory has helped refine the new technology being used in the study for isolating and purifying the islet cells to enhance their viability following transplantation.

The islet transplants will take place at the hospital, which has built a new state-of-the-art facility for the procedure and trial. In the transplant, islet cells are infused into the bloodstream, which carries them into the liver where they begin to produce insulin to normalize the blood sugar.

Although this research is ongoing and no conclusions are drawn, Kaufman said a majority of the subjects receiving the islet transplants to date have either achieved insulin independence for as long as three years or have required smaller amounts of insulin and had improved blood sugar control and quality of life. Currently, islet cell transplants are effective for three to five years.

Patients need to take immunosuppressive drugs to prevent rejection of the islet cells.

Previously, the only other option for patients with hard to control type 1 diabetes was a pancreas transplant. “This offers more options for individuals to become insulin free,” Kaufman said.

As more expertise is gained with this procedure and anti-rejection medications, more and more people may become candidates for it.

“Some day this technology will expand and allow us to transplant insulin producing tissue from expanded lines, for example from stem cells,” Kaufman said. “We hope one day it may be possible to isolate some cells from a donor pancreas and be able to multiply those cells a thousand fold, so instead of transplanting one individual, you could transplant 1,000.”

He added that the launch of this study is an important milestone marking the beginning of a new era in healthcare in which cellular transplants and regenerative medicine will be accessible to many people with disease, such as diabetes, to return them to a higher and healthier quality of life.

The study is seeking and enrolling subjects into this trial. To be eligible for the Islet Alone trials, subjects must have insulin dependent type 1 diabetes mellitus and suffer from hypoglycemic unawareness or have difficult to control “brittle” diabetes. For the Islet after Kidney trial, subjects with Type I Diabetes Mellitus who have a functional kidney transplant are also being recruited, including those who have had a prior failed pancreas transplant.

To learn more about the trial and islet transplantation, and to find out if you might qualify for the trial, please contact Elyse Stuart at 312-503-1060. You can also visit http://www.nmh.org/nmh/transplant/pancreasislet/islet.htm for information about islet transplantation.

Contact: Marla Paul at (312) 503-8928 or at
marla-paul@northwestern.edu

Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Comments are closed.

Latest News

Medical Education Day Celebrates Mentorship and Equity

Sep 29, 2023

Mapping Neural Activity Patterns and Odor Perception  

Sep 28, 2023

Lloyd-Jones Announces He is Stepping Down as Chair of Preventive Medicine

Sep 27, 2023

Small, Implantable Device Could Sense and Treat Cancer

Sep 26, 2023

Gene Linked to Glioblastoma Stem Cell Self-Renewal and Immunosuppression

Sep 26, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230927_MedEdDay_Sargent_6
20230927_MedEdDay_Sargent_3
20230927_MedEdDay_Sargent_1
20230927_MedEdDay_Posters_Patel_2
20230927_MedEdDay_Posters_Patel_1
20230927_MedEdDay_Posters_Panko_1
20230927_MedEdDay_Posters_4
20230927_MedEdDay_Posters_3
20230927_MedEdDay_Posters_2
20230927_MedEdDay_Posters_1
20230927_MedEdDay_Awards_6
20230927_MedEdDay_Awards_5

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.